Literature DB >> 28785832

A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.

Francesca Bianchi1, Elena Maccaroni2, Laura Belvederesi1, Cristiana Brugiati1, Riccardo Giampieri1, Federica Bini1, Raffaella Bracci1, Silvia Pagliaretta1, Michela Del Prete1, Francesco Piva3, Alessandra Mandolesi4, Marina Scarpelli4, Rossana Berardi1.   

Abstract

Lynch syndrome is caused by germline mutations in any of the MisMatch Repair (MMR) genes. About 37% of MSH2 variants are missense variants causing single amino-acid substitutions. Whether missense variants affect the normal function of MMR proteins is crucial both to provide affected families a more accurate risk assessment and to offer predictive testing to family members. Here we report one family, fulfilling both Amsterdam I and II criteria and Bethesda guidelines, referred to our center for genetic counselling. The proband and some of her relatives have been investigated for microsatellite instability (MSI), immunohistochemical MMR protein staining, direct sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA). Also Subcellular Localization Assay and Splice site predictions analyses were used. A germline missense variant of uncertain significance (exon 3, p.Val161Asp) was found in MSH2 gene in proband and in some relatives. The variant was associated with lack of expression of MSH2 protein (DMMR) and MSI-High status in tumour tissues. The localization assay of the MSH2 protein showed an abnormal subcellular localization pattern of the corresponding protein. Finally, splice-site prediction analysis ruled out a potential role of new splice sites as the cause behind the lack of expression of MSH2 protein and we suppose a potential correlation with other forms of post-transcriptional regulation (circular RNAs). The variant here reported shows a high correlation with phenotype and is located in an evolutionary conserved domain. The localization assay also suggest a potential pathogenic role, thus supporting further research on this matter.

Entities:  

Keywords:  Genetic testing; Germline mutation; Lynch syndrome; Missense variant; Pathogenic mutation

Mesh:

Substances:

Year:  2018        PMID: 28785832     DOI: 10.1007/s10689-017-0030-x

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  46 in total

1.  Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.

Authors:  Saara Ollila; Laura Sarantaus; Reetta Kariola; Philip Chan; Heather Hampel; Elke Holinski-Feder; Finlay Macrae; Maija Kohonen-Corish; Anne-Marie Gerdes; Päivi Peltomäki; Elisabeth Mangold; Albert de la Chapelle; Marc Greenblatt; Minna Nyström
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

2.  Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer.

Authors:  Jie Chen; Yan Li; Qiupeng Zheng; Chunyang Bao; Jian He; Bin Chen; Dongbin Lyu; Biqiang Zheng; Yu Xu; Ziwen Long; Ye Zhou; Huiyan Zhu; Yanong Wang; Xianghuo He; Yingqiang Shi; Shenglin Huang
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

3.  Using circular RNA as a novel type of biomarker in the screening of gastric cancer.

Authors:  Peifei Li; Shengcan Chen; Huilin Chen; Xiaoyan Mo; Tianwen Li; Yongfu Shao; Bingxiu Xiao; Junming Guo
Journal:  Clin Chim Acta       Date:  2015-02-14       Impact factor: 3.786

4.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 5.  Hereditary colorectal cancer syndromes.

Authors:  Lisa L Strate; Sapna Syngal
Journal:  Cancer Causes Control       Date:  2005-04       Impact factor: 2.506

6.  Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing.

Authors:  M Cravo; A J Afonso; P Lage; C Albuquerque; L Maia; C Lacerda; P Fidalgo; P Chaves; C Cruz; C Nobre-Leitão
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system.

Authors:  Laura Belvederesi; Francesca Bianchi; Eva Galizia; Cristian Loretelli; Raffaella Bracci; Romina Catalani; Monica Amati; Riccardo Cellerino
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Authors:  Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.

Authors:  Maria Armakola; Matthew J Higgins; Matthew D Figley; Sami J Barmada; Emily A Scarborough; Zamia Diaz; Xiaodong Fang; James Shorter; Nevan J Krogan; Steven Finkbeiner; Robert V Farese; Aaron D Gitler
Journal:  Nat Genet       Date:  2012-10-28       Impact factor: 38.330

View more
  1 in total

1.  Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type.

Authors:  Elena Maccaroni; Edoardo Lenci; Veronica Agostinelli; Valeria Cognigni; Riccardo Giampieri; Paola Mazzanti; Marzia Di Pietro Paolo; Francesca Bianchi; Cristiana Brugiati; Laura Belvederesi; Silvia Pagliaretta; Alessandra Mandolesi; Marina Scarpelli; Alberto Murrone; Francesca Morgese; Zelmira Ballatore; Rossana Berardi
Journal:  Explor Target Antitumor Ther       Date:  2021-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.